{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-055709","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.611066+00:00","generated_at":"2026-05-20T00:54:49.655825+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Traws Pharma reports 80% ORR, 50% CR for rigosertib in RDEB-SCC Phase 2 study","bullets":["Rigosertib Phase 2 ISS in RDEB-SCC showed 80% overall response rate (ORR) with 50% complete responses (CR) in evaluable patients.","Results published on June 3, 2025; study enrolled patients who failed prior immune checkpoint inhibitor therapy.","Company also posted corporate presentations for rigosertib and narazaciclib; narazaciclib trials are on hold pending funding.","Traws seeking partnership opportunities for rigosertib in RDEB-SCC, a high unmet need with no approved treatments.","Clinical safety database for rigosertib includes >1,300 patients across prior cancer studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-055709","json":"https://secwatch.observer/filing/0001104659-25-055709.json","markdown":"https://secwatch.observer/filing/0001104659-25-055709.md","text":"https://secwatch.observer/filing/0001104659-25-055709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925055709/0001104659-25-055709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925055709/tm2516986d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T00:54:49.655825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}